Fort Washington Investment Advisors Inc. OH Trims Holdings in Option Care Health, Inc. (NASDAQ:OPCH)

Fort Washington Investment Advisors Inc. OH decreased its holdings in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 16.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 790,420 shares of the company’s stock after selling 152,880 shares during the period. Fort Washington Investment Advisors Inc. OH owned 0.48% of Option Care Health worth $27,625,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of OPCH. Wellington Management Group LLP boosted its stake in shares of Option Care Health by 84.6% during the 4th quarter. Wellington Management Group LLP now owns 18,325,123 shares of the company’s stock valued at $425,143,000 after purchasing an additional 8,400,208 shares in the last quarter. Norges Bank bought a new position in Option Care Health in the fourth quarter worth about $60,219,000. Voloridge Investment Management LLC purchased a new stake in Option Care Health in the fourth quarter worth about $27,428,000. Freestone Grove Partners LP purchased a new stake in Option Care Health in the fourth quarter worth about $17,487,000. Finally, Dimensional Fund Advisors LP boosted its position in Option Care Health by 17.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,988,051 shares of the company’s stock valued at $92,518,000 after acquiring an additional 591,042 shares in the last quarter. Hedge funds and other institutional investors own 98.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on OPCH. JPMorgan Chase & Co. raised their target price on Option Care Health from $40.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, March 6th. JMP Securities reissued a “market outperform” rating and set a $36.00 price objective on shares of Option Care Health in a research report on Tuesday, April 22nd. UBS Group upgraded shares of Option Care Health from a “neutral” rating to a “buy” rating and boosted their target price for the company from $38.00 to $40.00 in a report on Wednesday, April 30th. Finally, Barrington Research reiterated an “outperform” rating and issued a $38.00 price target on shares of Option Care Health in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Option Care Health currently has a consensus rating of “Moderate Buy” and an average price target of $35.50.

Option Care Health Trading Up 0.6%

NASDAQ OPCH opened at $31.87 on Friday. Option Care Health, Inc. has a 12 month low of $21.39 and a 12 month high of $35.53. The stock has a market cap of $5.22 billion, a P/E ratio of 26.78, a P/E/G ratio of 2.30 and a beta of 0.74. The stock’s fifty day moving average price is $32.24 and its 200-day moving average price is $30.21. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77.

Option Care Health (NASDAQ:OPCH) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. The company had revenue of $1.33 billion for the quarter, compared to analysts’ expectations of $1.26 billion. Option Care Health had a net margin of 4.37% and a return on equity of 15.30%. Option Care Health’s revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.26 EPS. As a group, equities analysts forecast that Option Care Health, Inc. will post 1.22 EPS for the current fiscal year.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.